Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-08-21
DOI
10.3389/fimmu.2023.1203073
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
- (2023) Toan D. Nguyen et al. Cancers
- Bis‐ethynylphosphonamidates as an Modular Conjugation Platform to Generate Multi‐Functional Protein‐ and Antibody‐Drug‐Conjugates
- (2022) Marc‐André Kasper et al. EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
- Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
- (2022) Rotimi Sheyi et al. Pharmaceutics
- Antibody–drug conjugates in solid tumors: a look into novel targets
- (2021) Carmen Criscitiello et al. Journal of Hematology & Oncology
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
- (2021) Louise Conilh et al. Pharmaceuticals
- Neoantigen: A New Breakthrough in Tumor Immunotherapy
- (2021) Zheying Zhang et al. Frontiers in Immunology
- T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy
- (2021) Zhijian Duan et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- How to select IgG subclasses in developing anti-tumor therapeutic antibodies
- (2020) Jifeng Yu et al. Journal of Hematology & Oncology
- Recent advances of antibody drug conjugates for clinical applications
- (2020) Pengxuan Zhao et al. Acta Pharmaceutica Sinica B
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates
- (2019) Marc-André Kasper et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis
- (2019) Mingyan Cao et al. mAbs
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates
- (2019) Wei Li et al. ACS Medicinal Chemistry Letters
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
- (2018) Hui Zhao et al. CANCER RESEARCH
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- 949PMirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
- (2018) U A Matulonis et al. ANNALS OF ONCOLOGY
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Current progress in innovative engineered antibodies
- (2017) William R. Strohl Protein & Cell
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?
- (2016) Janine Schuurman et al. CURRENT OPINION IN IMMUNOLOGY
- Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
- (2016) Carolin Sellmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Advances in Antibody Design
- (2015) Kathryn E. Tiller et al. Annual Review of Biomedical Engineering
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Evolving Strategies for Target Selection for Antibody-Drug Conjugates
- (2015) Marc Damelin et al. PHARMACEUTICAL RESEARCH
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- An FDA oncology analysis of antibody-drug conjugates
- (2015) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- A mechanistic compartmental model for total antibody uptake in tumors
- (2012) Greg M. Thurber et al. JOURNAL OF THEORETICAL BIOLOGY
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
- (2008) Herbert Riechelmann et al. ORAL ONCOLOGY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started